Gabriel Peixoto

Senior Research Associate II at Ambys Medicines

Gabriel Peixoto has a wealth of work experience. From 2013 to 2019, they held various roles in research, including Undergraduate Student Researcher at San Francisco State University, Graduate Research Student at University of California, San Francisco, and Junior Specialist at University of California, San Francisco. From 2019 onwards, they have been a Senior Research Associate II at Ambys Medicines, where they developed 3D co-cultured cell-therapy models of primary human hepatocytes for liver disease rescue. Gabriel also screened candidates for effective cell therapy and tested effective dosage/conditions for effective engraftment in vivo. Additionally, they isolated, cultured, and characterized human and mouse primary liver cells (Hepatocyte, Hepatic Stellate cells, Kupffer cells, and endothelial cells). Gabriel managed CROs and cross-functional collaborations with multiple teams, and trained several team members across departments to set company-wide standards of experimental procedures.

Gabriel Peixoto attended San Francisco State University from 2012 to 2015, where they earned a Bachelor of Science in Cell/Cellular and Molecular Biology. Gabriel then went on to pursue a Master of Science in Stem Cell Biology at the same university, which they completed in 2017. Gabriel also attended the University of California, San Francisco, where they obtained a Master of Science, though the field of study is unknown.

Location

San Francisco, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Ambys Medicines

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.